387 related articles for article (PubMed ID: 16804036)
1. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
Mehta RV; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
[TBL] [Abstract][Full Text] [Related]
2. Comparison of follicle-stimulating-hormone-stimulated dimeric inhibin and estradiol responses as indicators of granulosa cell function in polycystic ovary syndrome and normal women.
Wachs DS; Coffler MS; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2006 Aug; 91(8):2920-5. PubMed ID: 16720653
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
4. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome.
Coffler MS; Patel K; Dahan MH; Malcom PJ; Kawashima T; Deutsch R; Chang RJ
J Clin Endocrinol Metab; 2003 Apr; 88(4):1742-7. PubMed ID: 12679467
[TBL] [Abstract][Full Text] [Related]
5. Hormonal effects of flutamide in young women with polycystic ovary syndrome.
De Leo V; Lanzetta D; D'Antona D; la Marca A; Morgante G
J Clin Endocrinol Metab; 1998 Jan; 83(1):99-102. PubMed ID: 9435423
[TBL] [Abstract][Full Text] [Related]
6. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women.
Wachs DS; Coffler MS; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2007 May; 92(5):1871-4. PubMed ID: 17299061
[TBL] [Abstract][Full Text] [Related]
8. Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.
Wachs DS; Coffler MS; Malcom PJ; Shimasaki S; Chang RJ
J Clin Endocrinol Metab; 2008 May; 93(5):1827-33. PubMed ID: 18285408
[TBL] [Abstract][Full Text] [Related]
9. Concerted stimulation of rat granulosa cell deoxyribonucleic acid synthesis by sex steroids and follicle-stimulating hormone.
Bley MA; Saragüeta PE; Barañao JL
J Steroid Biochem Mol Biol; 1997 May; 62(1):11-9. PubMed ID: 9366494
[TBL] [Abstract][Full Text] [Related]
10. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
11. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
Adams JM; Taylor AE; Crowley WF; Hall JE
J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
[TBL] [Abstract][Full Text] [Related]
13. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
14. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.
Guedikian AA; Lee AY; Grogan TR; Abbott DH; Largaespada K; Chazenbalk GD; Dumesic DA
Fertil Steril; 2018 Mar; 109(3):508-515. PubMed ID: 29428312
[TBL] [Abstract][Full Text] [Related]
15. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries.
Willis D; Mason H; Gilling-Smith C; Franks S
J Clin Endocrinol Metab; 1996 Jan; 81(1):302-9. PubMed ID: 8550768
[TBL] [Abstract][Full Text] [Related]
16. Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism.
Smyth CD; Miró F; Whitelaw PF; Howles CM; Hillier SG
Endocrinology; 1993 Oct; 133(4):1532-8. PubMed ID: 8404591
[TBL] [Abstract][Full Text] [Related]
17. Role of androgens in the regulation of the human menstrual cycle.
Rossmanith WG; Schenkel B; Benz R
Gynecol Endocrinol; 1994 Sep; 8(3):151-9. PubMed ID: 7847099
[TBL] [Abstract][Full Text] [Related]
18. Recombinant follicle-stimulating hormone stimulates ovarian androgen synthesis in down-regulated ovulatory women.
Tanbo T; Dale PO; Abyholm T
Gynecol Endocrinol; 2001 Dec; 15(6):407-12. PubMed ID: 11826763
[TBL] [Abstract][Full Text] [Related]
19. Ovulatory effects of flutamide in the polycystic ovary syndrome.
Paradisi R; Fabbri R; Battaglia C; Venturoli S
Gynecol Endocrinol; 2013 Apr; 29(4):391-5. PubMed ID: 23327685
[TBL] [Abstract][Full Text] [Related]
20. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
